
FibroGen (Mon, Apr 22, 2024)

Sell candidate since Apr 03, 2024 Loss -22.45%



StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania

#18225/30110

Trend MV Long: Sell MV Short: Sell Sell Volume: Sell MACD: Sell

Tech commentaries:

The FibroGen stock price fell by -0.87% on the last day (Monday, 22nd Apr 2024) from \$1.15 to \$1.14. It has now fallen 5 days in a row. During the last trading day the stock fluctuated 8.33% from a day low at \$1.08 to a day high of \$1.17. The price has fallen in 9 of the last 10 days and is down by -30.06% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -525 thousand shares and in total, 785 thousand shares were bought and sold for approximately \$895.26 thousand.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -7.73% during the next 3 months and, with a 90% probability hold a price between \$0.626 and \$2.36 at the end of this 3-month period.

There are few to no technical positive signals at the moment. The FibroGen stock holds sell signals from both short and longterm Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at \$1.23 and \$1.85. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, February 09, 2024, and so far it has fallen -58.24%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

FibroGen finds support from accumulated volume at \$1.10 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance just above today's level from accumulated volume at \$1.15, \$1.17 and \$1.30.

This stock may move very much during the day (volatility) and with periodic low trading volume this stock is considered to be "very high risk". During the last day, the stock moved \$0.0900 between high and low, or 8.33%. For the last week the stock has had daily average volatility of 9.83%.

FibroGen holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Risk: Very High

Evaluation: Strong Sell Candidate